Article info

Download PDFPDF
Paper
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
  1. Correspondence to Rami Moucari, Service d'Hépatologie et INSERM U773-CRB3, Hôpital Beaujon, Clichy, France; rmoucari{at}yahoo.com
View Full Text

Citation

Moucari R, Forestier N, Larrey D, et al
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C

Publication history

  • Revised June 25, 2010
  • Accepted June 30, 2010
  • First published September 21, 2010.
Online issue publication 
November 11, 2010

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.